ATE302015T1 - Zusammensetzung, welche apoptosis verhindert, methode zur reinigung dieser zusammensetzung und verwendungen davon - Google Patents

Zusammensetzung, welche apoptosis verhindert, methode zur reinigung dieser zusammensetzung und verwendungen davon

Info

Publication number
ATE302015T1
ATE302015T1 AT95903617T AT95903617T ATE302015T1 AT E302015 T1 ATE302015 T1 AT E302015T1 AT 95903617 T AT95903617 T AT 95903617T AT 95903617 T AT95903617 T AT 95903617T AT E302015 T1 ATE302015 T1 AT E302015T1
Authority
AT
Austria
Prior art keywords
composition
purifying
prevents apoptosis
compositions
methods
Prior art date
Application number
AT95903617T
Other languages
English (en)
Inventor
Ian Cyril Bathurst
John D Bradley
L David Tomei
Philip J Barr
Original Assignee
Sky High Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sky High Llc filed Critical Sky High Llc
Application granted granted Critical
Publication of ATE302015T1 publication Critical patent/ATE302015T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
AT95903617T 1993-11-30 1994-11-30 Zusammensetzung, welche apoptosis verhindert, methode zur reinigung dieser zusammensetzung und verwendungen davon ATE302015T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15898093A 1993-11-30 1993-11-30
US08/320,155 US5759548A (en) 1993-11-30 1994-10-07 Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
PCT/US1994/013649 WO1995015173A1 (en) 1993-11-30 1994-11-30 Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof

Publications (1)

Publication Number Publication Date
ATE302015T1 true ATE302015T1 (de) 2005-09-15

Family

ID=26855549

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95903617T ATE302015T1 (de) 1993-11-30 1994-11-30 Zusammensetzung, welche apoptosis verhindert, methode zur reinigung dieser zusammensetzung und verwendungen davon

Country Status (14)

Country Link
US (8) US5759548A (de)
EP (1) EP0732930B1 (de)
JP (2) JPH11501284A (de)
KR (1) KR960706350A (de)
CN (1) CN1140998A (de)
AT (1) ATE302015T1 (de)
AU (1) AU678090B2 (de)
CA (1) CA2177825A1 (de)
DE (1) DE69434459T2 (de)
FI (1) FI962246L (de)
HU (1) HUT76096A (de)
NO (1) NO962187L (de)
NZ (1) NZ277403A (de)
WO (1) WO1995015173A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2161771C (en) * 1993-04-30 2009-01-13 L. David Tomei Methods of identifying potentially therapeutically effective agents and cell strains for use therein
US5759548A (en) * 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US5620888A (en) * 1994-12-29 1997-04-15 Lxr Biotechnology, Inc. Cell strains for use in identifying potentially therapeutically effective agents
CN1200036A (zh) * 1995-09-14 1998-11-25 Lxr生物技术有限公司 含有磷脂混合物并具有抗细胞程序死亡活性的组合物
CA2250219C (en) 1996-03-28 2008-10-07 Hayat Onyuksel Materials and methods for making improved liposome compositions
AU2814897A (en) * 1996-04-25 1997-11-12 T Cell Sciences, Inc. Method of isolating regulators of t cell activation
US5955269A (en) * 1996-06-20 1999-09-21 Rutgers, The State University Of New Jersey Methods of screening foods for nutraceuticals
US20070299005A1 (en) 1996-09-24 2007-12-27 Tanox, Inc. Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
ES2263181T5 (es) 1996-09-24 2011-04-07 Genentech, Inc. Una familia de genes que codifican péptidos relacionados con la apoptosis, péptidos codificados por ellos y los métodos de uso de los mismos.
IL119535A (en) * 1996-10-31 2001-01-11 Chajuss Daniel Soy molasses and modified soy molasses for topical application
US6180402B1 (en) 1996-11-20 2001-01-30 Qlt Inc. Method for inhibiting apoptosis induced by photodynamic therapy using a cysteine or serine protease inhibitor
WO1998035551A1 (en) 1997-02-13 1998-08-20 Lxr Biotechnology Inc. Organ preservation solution
US6495532B1 (en) * 1997-03-19 2002-12-17 Sky High, Llc Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
US6217886B1 (en) 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
WO1999008514A1 (en) * 1997-08-20 1999-02-25 Lxr Biotechnology, Inc. Compositions containing polyethylene glycol and uses thereof
EP0911634A1 (de) * 1997-10-24 1999-04-28 Het Nederlands Kanker Instituut Pharmazeutische Verwendungen von Regulatoren der CDK-2
US6949528B1 (en) * 1998-03-18 2005-09-27 Goddard John G Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
AU3191599A (en) 1998-03-18 1999-10-11 Lxr Biotechnology Inc. Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
US5869063A (en) * 1998-06-29 1999-02-09 Protease Sciences, Inc. Dermatological and cosmetic compositions containing marama bean extract
US6045990A (en) * 1998-07-09 2000-04-04 Baust; John M. Inclusion of apoptotic regulators in solutions for cell storage at low temperature
US6413556B1 (en) 1999-01-08 2002-07-02 Sky High, Llc Aqueous anti-apoptotic compositions
WO2000051624A2 (en) * 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Methods and compositions useful in inhibiting apoptosis
US6849605B1 (en) 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
WO2000051625A1 (en) * 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
WO2000051623A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
AU4213500A (en) * 1999-04-09 2000-11-14 Cytovia, Inc. Caspase inhibitors and the use thereof
BR0013666A (pt) 1999-08-27 2002-05-14 Cytovia Inc "alfa"-hidróxi-ácidos substituìdos inibidores de caspases e o seu uso
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
AU2580801A (en) * 1999-12-14 2001-06-25 Sky High, Llc Phospholipid compositions as anti-inflammation agents
US20070048726A1 (en) * 2000-01-14 2007-03-01 Biolife Solutions, Inc. Methods and Compositions for the Control of Molecular-Based Cell Death During Preservation of Cells, Tissues or Organs in a Gel-Like State
US20060063738A1 (en) * 2000-02-28 2006-03-23 Sky High, Llc Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
US6861077B1 (en) * 2000-03-17 2005-03-01 L'oreal S.A. Use of plant extracts in a cosmetic composition to protect keratinous fibers
US20030130237A1 (en) * 2000-03-17 2003-07-10 Miller Duane D. LPA receptor agonists and antagonists and methods of use
WO2003015794A1 (en) * 2001-08-20 2003-02-27 Tatton Technologies, Llc. Methods and compositions for treating apoptosis associated disorders
US20030077264A1 (en) * 2001-09-20 2003-04-24 Goodrich Laura L. Antimicrobial blood treatment using allicin and related compounds
PT1941867E (pt) 2002-06-07 2012-02-16 Dyax Corp Polipeptídeo contendo um domínio kunitz modificado
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
DK2386310T3 (en) * 2002-08-28 2019-02-25 Dyax Corp Methods of preserving organs and tissues
CA2497819A1 (en) * 2002-09-13 2004-03-25 Ronald N. Caron Age-hardening copper-base alloy and processing
EP1398019A1 (de) 2002-09-13 2004-03-17 Cognis France S.A. Verfahren zum Schutz und zur Modulation von Dermal Epidermal Junctions
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
US7829277B2 (en) 2004-03-01 2010-11-09 The Regents Of The University Of California Methods for identifying compounds that suppress chemically-induced carcinogenesis
US20060035827A1 (en) * 2004-06-24 2006-02-16 Green Gary M Compositions and methods for the treatment or prevention of gallbladder disease
US7691417B2 (en) 2004-09-02 2010-04-06 Clemson University Research Foundation Tumor and mutation suppressing plant extract
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
US8187643B2 (en) * 2007-03-28 2012-05-29 Greg Steininger, legal representative Shampoo formulation for treatment of hair loss and method of use
WO2010005560A2 (en) * 2008-07-07 2010-01-14 Woods Hole Oceanographic Institution Methods for obtaining bioactive compounds from phytoplankton
JP2013516389A (ja) * 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
US8362013B2 (en) * 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US20100280031A1 (en) * 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
TWI540132B (zh) * 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
WO2011057132A1 (en) * 2009-11-05 2011-05-12 Woods Hole Oceanographic Institution Methods for obtaining bioactive compounds from phytoplankton
BR112012014499A2 (pt) * 2009-12-22 2016-08-16 Abbott Lab cápsula de abt-263
HRP20181419T1 (hr) 2010-01-06 2018-11-16 Dyax Corp. Plazma kalikrein vezni proteini
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp Plasma kallikrein binding proteins
KR102555955B1 (ko) 2014-03-27 2023-07-18 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
WO2017100679A1 (en) 2015-12-11 2017-06-15 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4340586A (en) * 1977-02-18 1982-07-20 Adam Bekierkunst Pharmaceutical preparation for treating disorders of the skin
JPS54117034A (en) * 1978-02-28 1979-09-11 Nippon Shoji Kk Treating agent for consciousness and perception motion disorder
ATE73345T1 (de) * 1984-10-19 1992-03-15 Chiron Corp Anregung zur heilung einer wunde mittels menschlichen hautwachstumsfaktors hergestellt durch rekombinant-dns.
US4793996A (en) * 1984-11-14 1988-12-27 Ann R. Kennedy Method of making soybean extract inhibitor
US4818540A (en) * 1985-02-25 1989-04-04 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
JPS62155082A (ja) * 1985-12-27 1987-07-10 Karupisu Shokuhin Kogyo Kk ビフイズス菌増殖物質の製造法
US4695590A (en) * 1986-05-05 1987-09-22 California Health Technologies Method for retarding aging
JPS6351335A (ja) * 1986-08-20 1988-03-04 Fuji Oil Co Ltd 肥満細胞脱顆粒抑制剤
US4746652A (en) * 1986-11-18 1988-05-24 Wake Forest University Method of inducing diuresis with lysophospholipids
US4959310A (en) * 1987-09-28 1990-09-25 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to soybean kunitz trypsin inhibitor and immunoassay methods
US5053327A (en) * 1988-09-20 1991-10-01 The United States Of America As Represented By The Secretary Of Agriculture High affinity monoclonal antibodies to bowman-birk inhibitor and immunoassay methods
US5140043A (en) * 1989-04-17 1992-08-18 Duke University Stable ascorbic acid compositions
US4938961A (en) * 1989-04-28 1990-07-03 Geoffrey Collins Organ preservation solution containing pokyethylene gycol and method of performing cardioplegia
US5130298A (en) * 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
JP2809429B2 (ja) * 1989-05-26 1998-10-08 湧永製薬株式会社 制ガン剤ならびに制ガン剤として有用な新規複素環化合物またはそれらの塩
US5376373A (en) * 1990-09-06 1994-12-27 Trustees Of The University Of Pennsylvania Method of inhibiting radiation induced weight and hair loss
US5217717A (en) * 1990-09-06 1993-06-08 Central Soya Company, Inc. Method of making soybean Bowman-Birk inhibitor concentrate and use of same as a human cancer preventative and therapy
US5238965A (en) * 1991-05-31 1993-08-24 The Procter & Gamble Company Methods of using lysophosphatidic acids for regulating skin wrinkles
US5340568A (en) * 1992-07-01 1994-08-23 The Procter & Gamble Company Topical composition and method containing deoxy and halo derivatives of lysophosphatidic acids for regulating skin wrinkles
US5636187A (en) 1992-12-11 1997-06-03 Canon Kabushiki Kaisha Magnetooptical recording apparatus and magnetooptical recording method for canceling leakage magnetic fields associated with a recording medium and devices ancillary to the recording medium
US5277917A (en) * 1993-04-02 1994-01-11 Allelix Biopharmaceuticals Inc. Ovarian cancer ascites factor, in isolated form
CA2161771C (en) * 1993-04-30 2009-01-13 L. David Tomei Methods of identifying potentially therapeutically effective agents and cell strains for use therein
US5330972A (en) * 1993-05-28 1994-07-19 Abbott Laboratories Method of impeding apoptosis of CD4 cells in persons infected with human immunodeficiency virus
NZ248603A (en) * 1993-05-28 1994-12-22 Abbott Lab Nutritional product for enteral nutritional support of hiv victims comprising proteins and fat
US5759548A (en) * 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof

Also Published As

Publication number Publication date
AU1261295A (en) 1995-06-19
KR960706350A (ko) 1996-12-09
US5620885A (en) 1997-04-15
FI962246A7 (fi) 1996-07-22
US5635187A (en) 1997-06-03
CN1140998A (zh) 1997-01-22
US5759548A (en) 1998-06-02
JPH11501284A (ja) 1999-02-02
NO962187D0 (no) 1996-05-29
JP2007084573A (ja) 2007-04-05
EP0732930A1 (de) 1996-09-25
US5567425A (en) 1996-10-22
US5635186A (en) 1997-06-03
FI962246A0 (fi) 1996-05-29
DE69434459T2 (de) 2006-04-06
US20020110608A1 (en) 2002-08-15
CA2177825A1 (en) 1995-06-08
US5624672A (en) 1997-04-29
US6656729B2 (en) 2003-12-02
US6306398B1 (en) 2001-10-23
NO962187L (no) 1996-07-30
WO1995015173A1 (en) 1995-06-08
DE69434459D1 (de) 2005-09-22
HUT76096A (en) 1997-06-30
EP0732930B1 (de) 2005-08-17
EP0732930A4 (de) 1997-10-29
NZ277403A (en) 1998-03-25
AU678090B2 (en) 1997-05-15
FI962246L (fi) 1996-07-22
HU9601449D0 (en) 1996-07-29

Similar Documents

Publication Publication Date Title
ATE302015T1 (de) Zusammensetzung, welche apoptosis verhindert, methode zur reinigung dieser zusammensetzung und verwendungen davon
EA200601553A1 (ru) Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
BR9900320A (pt) Composição antimicrobiana
DE69831566D1 (de) Probucol monoester zur behandlung von kreislauf- und entzündungserkrankungen
DK0705100T3 (da) Terapeutiske substituerede guanidiner
ATE259215T1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
DE60122767D1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
DE60120691D1 (de) Zusammensetzungen zur verwendung bei der behandlung der osteoporose und/oder der entzündlichen gelenkerkrankungen
ATE405840T1 (de) Zusammensetzungen und verfahren zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung
UA39166C2 (uk) Похідні n-гідроксисечовини, що є інгібіторами ліпоксигенази у ссавців, спосіб їх одержання і спосіб інгібування ліпоксигенази у ссавців
AP0202539A0 (en) Inhibitors of interleukin -1B converting enzyme
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
BG102818A (en) D-manitol and method for its preparation
DE60141636D1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
ITMI931649A1 (it) Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
DE60235836D1 (de) Ahren und verwendung davon
ATE302613T1 (de) Proteinfarnesyltransferase-inhibitoren in kombination mit hmgcoa-reduktase-inhibitoren zur behandlung von aids
DE69333711D1 (de) Compactin zur behandlung von entzündungen
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DE69614824D1 (de) Verfahren zur herstellung von retrovial protease hemmenden zwischenprodukten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties